Trump Administration

The Trump administration issues a call to action based on new data detailing the COVID-19 impact, on Medicare beneficiaries, CMS announces. Older Americans as well as those with chronic conditions are at more risk fro COVID-19 confirming the disparities in health outcomes for racial and ethnic minority groups and low-income […]

Medicare Beneficiaries & COVID-19: Trump Administration Call to Action

 in Medicare  tagged COVID-19 / Dual Eligible / insurance questions / Medicare Beneficiaries / Medicare Beneficiaries & COVID-19 / Trump Administration by
CMS rules are receiving a change that gives states more flexibility to enter into value-based purchasing agreements with drugmakers for new and pricey products. This proposed change in rule by the Trump administration will remove current barriers that allow each state to develop these agreements with current drug companies. CMS […]

CMS Rules Are Receiving a Change Involving Drug Agreements

 in Uncategorized  tagged drug manufacturer and state agreements / drug pricing / insurance questions / new CMS rules / New Payment Arrangements / Pricing Best Practices for drugs / State & Drug Manufacturers Flexibility / Trump Administration by